This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

LX4211 Phase 2b Results Presented At American Heart Association Annual Conference

THE WOODLANDS, Texas, Nov. 6, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.  The oral presentation is being delivered by Dr. Julio Rosenstock, Director of the Dallas Diabetes and Endocrine Center at Medical City, lead investigator in the recently completed study.

"The results from this trial demonstrate potential benefits of inhibiting SGLT1 in addition to the known effects of SGLT2 inhibition, not only in improving glycemic control, but also in achieving reductions in important cardiovascular risk factors such as blood pressure and body weight with an apparent favorable safety profile that will need confirmation by long-term controlled trials," said Dr. Rosenstock.  

LX4211, an investigational, oral, dual inhibitor of sodium glucose co-transporters 1 and 2 (SGLT1 and SGLT2), reduces the amount of glucose that enters the bloodstream from the gastrointestinal (GI) tract by inhibiting SGLT1, the major transporter responsible for glucose absorption, and enhances glucose excretion in the urine by inhibiting SGLT2, the major transporter responsible for glucose reabsorption by the kidney. In the trial, LX4211 was tested in 299 patients with poorly controlled type 2 diabetes on metformin therapy. Patients were randomized to receive LX4211 at doses of 75 mg QD, 200 mg QD, 200 mg BID, 400 mg QD, or placebo for 12 weeks. New data presented today showed that maximal 24-hour urinary glucose excretion occurred at 200 mg QD dose, whereas maximal HbA1c reduction was obtained at the 400 mg QD dose. This suggests that dual inhibition of SGLT1 and SGLT2 offers the opportunity to achieve improved glycemic control with lower urinary glucose excretion relative to compounds that are selective for SGLT2.  These findings are consistent with previous studies that indicate LX4211's inhibition of SGLT1 in the GI tract reduces post-prandial glucose levels, resulting in a lower glucose load to be filtered by the kidney.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs